Roche gets USFDA nod to Tecentriq-Avastin combination to treat liver cancer
Zurich: Swiss drugmaker Roche said on Friday that the U.S. Food and Drug Administration (FDA) approved its immunotherapy Tecentriq in combination with its drug Avastin for the most common kind of liver cancer.Also Read: Roche Mixes Actemra With Gilead's Remdesivir In New COVID-19 Trial The Tecentriq-Avastin mix for unresectable or metastatic hepatocellular carcinoma was approved under the...
Zurich: Swiss drugmaker Roche said on Friday that the U.S. Food and Drug Administration (FDA) approved its immunotherapy Tecentriq in combination with its drug Avastin for the most common kind of liver cancer.
Also Read: Roche Mixes Actemra With Gilead's Remdesivir In New COVID-19 Trial
The Tecentriq-Avastin mix for unresectable or metastatic hepatocellular carcinoma was approved under the FDA's Real-Time Oncology Review pilot and Project Orbis initiative aimed at speedier access for patients, Roche said. The American Cancer Society estimated that more than 42,000 Americans will be diagnosed with liver cancer this year.
Headquarters in Basel, Roche is a multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.
Read also: Roche mixes Actemra with Gilead's remdesivir in new COVID-19 trial
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd